A 66-year-old man who suffered from an acute exacerbation of interstitial pneumonia developed a cavitary lesion after taking immunosuppressive drugs. He was diagnosed with cytomegalovirus (CMV) pneumonia. CMV was not thought to be the underlying cause of the cavitary lung lesions, as only six cases have been described thus far. However, this case clearly demonstrates that the development of cavitary lung lesions can be caused by CMV. Following CMV pneumonia, cavitary lesions again occurred in the patient's lungs that were thought to be the first case of cavitary lesions caused by Nocardia asiatica infection.
Introduction
Making a differential diagnosis of cavitary lung disease in immunocompromised patients can be difficult due to variations in disease presentation. Cavitary lesions have been reported in only six cases of cytomegalovirus (CMV) pneumonia (1-5) and have not been previously associated with Nocardia asiatica.
We herein present the case of a patient with cavitary lesions caused by CMV pneumonia and N. asiatica.
Case Report
A 66-year-old man was referred to our hospital due to a one-month history of dyspnea on exertion. On his initial visit (day 0), a chest X-ray showed bilateral reticular shadows in both lung fields (Fig. 1A) . Non-enhanced thoracic computed tomography (CT) revealed ground glass opacities with patchy consolidation primarily scattered in the middle to lower lobes (Fig. 1B) . The patient had undergone thymectomy once at 58 years of age and again at 63 years of age and was diagnosed with thymoma both times, thus suggesting the presence of recurrence. He had received treatment over three months for essential hypertension and chronic obstructive lung disease (GOLD stage II). He was a current smoker with a 75 pack-year history of smoking. His vital signs were as follows: blood pressure: 102/70 mmHg; heart rate: 88 beats/min; respiratory rate: 18 breaths/min; body temperature: 37.2°C; and oxygen saturation: 90% with an oxygen supply of 2 L/min delivered via nasal cannula. On physical examination, late inspiratory crackles were noted in the bilateral lower lung fields. The patient's laboratory data were normal, except for elevated levels of lactate dehydrogenase (382 IU/L), C-reactive protein (4.3 mg/dL), anti-Jo-1 antibody (49.8 U/mL), KL-6 (5,437 U/mL) and SP-D (995 On hospital admission, the patient did not satisfy any of the diagnostic criteria for polymyositis/dermatomyositis (PM/DM) (6, 7) provided by Bohan A and Peter JB. Therefore, based on a diagnosis of an acute exacerbation of interstitial pneumonia, the patient was intensively treated with steroid pulse therapy (1 g/day), cyclosporine (200 mg/body) and intravenous cyclophosphamide (500 mg/body) (Fig. 2) . His respiratory condition improved, and maintenance therapy with oral prednisolone (1 mg/kg/day) and cyclosporine (2 mg/kg/day) was initiated.
A prophylactic dose of trimethoprim-sulfamethoxazole (80 mg/400 mg) was discontinued on day 22 due to the possibility of drug-induced thrombocytopenia (platelet count: 8.9×10 4 /μL). However, the patient had persistent thrombocytopenia and developed a low-grade fever on day 38. Thoracic CT performed on day 39 showed a small (10-mm) cavitary lesion in left S3 (Fig. 2 , white arrow), which by day 55 had progressed to a cavity measuring 44 mm in size ( Bronchoscopy performed on day 59 revealed intraluminal ulcers (Fig. 3A , B white arrow) located at the bifurcation of the left upper bronchus (Fig. 3A , asterisk) and lingular segment (Fig. 3A , double asterisk) as well as at the orifice of left upper B 1+2 (Fig. 3B) . Bronchial brush cytology of these lesions was negative for malignancy, and bronchoalveolar lavage fluid was negative for bacteria, mycobacteria and fungi. However, CMV infection was confirmed based on the findings of a shell-vial culture of bronchial washing fluid obtained from left S3 and a CMV-DNA polymerase chain reaction of swollen alveolar epithelial cells with intranuclear inclusions bodies (Fig. 3C) . Based on the diagnosis of CMV pneumonia, treatment with ganciclovir (5 mg/kg) via intravenous infusion every 12 hours was commenced. Two weeks after the start of treatment (day 73), chest X-ray (Fig. 4A ) revealed two new nodules measuring 15 and 20 mm in size in the left upper and middle lung fields, respectively. Non-enhanced thoracic CT performed on the same day showed these new cavitary lesions to be located in left S 1+2 (Fig. 4C , arrow) and left S4 (Fig. 4E, arrowhead) . The previously recognized cavity in left S3 (Fig. 4C) had decreased in wall thickness, and the level of CMV antigenpositive leukocytes had decreased from 1,567 to 2. At that point, both serum (1 3)-β-D-glucan and Aspergillus antigen tests were positive (Fig. 2) . Under a suspicion of aspergillosis, treatment with micafungin was commenced intravenously. However, chest X-ray performed on day 80 (Fig. 4B) showed that the two lesions had progressed in size despite treatment with micafungin (300 mg/day) followed by voriconazole (400 mg/day). Bronchoscopy was performed again on day 88. The bronchial wash fluid obtained from the lingular segment was found to be negative for Aspergillus but positive for Nocardia sp. based on a culture. Therefore, the patient was diagnosed with CMV pneumonia followed by Nocardia sp. infection presenting as cavitary lesions one month after the original diagnosis. He was also treated intravenously with amikacin (400 mg/day) and imipenem (1.5 g/day) for Nocardia pneumonia.
Our patient continued to have a low level of CMV antigenemia even after two weeks of treatment (Fig. 2) , and two months after the first treatment, he experienced a recurrence of CMV infection presenting as retinitis that required retreatment with ganciclovir. Following resolution of the CMV retinitis, the patient was discharged uneventfully. Nocardia asiatica was identified in a 16S ribosomal DNA analysis. Thereafter, subsequent oral treatment with amoxicillin/clavulanate (1 g/day) and minocycline (200 mg/day) administered over six months resulted in resolution of the pneumonia.
Discussion
CMV pneumonia is a common life-threatening complication seen in immunocompromised patients, such as the patient presented in this report. Franquet et al. (8) reported that the primary radiological manifestation of CMV pneumonia on thoracic CT is a mixture of patterns, most commonly including ground-glass attenuation, areas of consolidation and nodules smaller than 10 mm in diameter. The development of cavitary lesions is extremely rare, with only six cases having been reported (Table) (1, 2-5). In these reports, the male to female ratio was 1.0 and the mean patient age ± SD was 45.2±15. Five patients had underlying diseases (four patients had systemic lupus erythematosus and one patient had rheumatoid arthritis) and were receiving immunosuppressive treatment, although only one patient was immunocompetent. Interestingly, previous reports also showed that the number of cavitary lesions in the lungs was one to two per individual case with lesions larger than 30 mm in all cases, as observed in the present case.
The clinical manifestations of CMV pneumonia can be nonspecific and are often difficult to diagnose. Previous cases (4, 5) have involved the development of persistent thrombocytopenia, lymphopenia (9) and hypogammaglobulinemia (10), even after the withdrawal of drugs. In the present case, the two former findings were noted; however, no 
Table. Summary of Clinical Data and Treatments for Previously Reported Cases of CMV Pneumonia Presenting with Cavitary Lesions
hypogammaglobulinemia was observed. Furthermore, our patient exhibited no evidence of other immunodeficiencies (e.g., Good's syndrome) associated with thymoma.
Although there is no recommended standard duration for ganciclovir treatment for patients with CMV pneumonia, the medication is commonly administered for two to three weeks. Our patient had a low level of CMV antigenemia even after two weeks of treatment (Fig. 2) , highlighting the critical issue of whether immunocompromised patients should be treated until negative results for serum CMV antigenemia are obtained. The pathogenesis underlying the generation of lung cavities in patients with CMV infection is not precisely known due to a lack of data, although Sutherland et al. reported that CMV (11) has the ability to initiate the generation of thrombin. Even though there is no evidence, this might result in the development of thrombosis in smaller vessels, resulting in necrosis in the lung parenchyma together with endothelial cell damage.
In 2004, Kageyama et al. (12) first described a new species of Nocardia, N. asiatica. Following this, five more strains were isolated in Asia between 1985 and 1999 from patients with nocardiosis in Japan and from clinical specimens in Thailand. Three strains were isolated from sputum, one strain was isolated from a granuloma and one strain was isolated from transtracheal aspirate. However, since 1999, only a few new cases have been reported (13, 14) . In the present case, two cavitary lesions (left S 1+2 , left S4) did not respond to ganciclovir, micafungin or voriconazole and were identified as being smaller lesions measuring less than 30 mm (Fig. 4C, E) . These lesions disappeared six months after the completion of targeted treatment for N. asiatica, which was identified in a 16s ribosomal DNA analysis, thus suggesting that these two cavitary lesions were caused by N. asiatica infection.
There are a few reports of pulmonary nocardiosis caused by N. asiatica (14, 15) . Liu et al. (15) reported that N. asiatica causes pneumonia and cutaneous infections, particularly in immunocompromised patients, such as those with HIV infection or bone marrow transplant recipients, as in the present case. However, the exact radiological findings typical of patients with N. asiatica infection remain unknown. To the best of our knowledge, this is the first report of a lung cavitary lesion resulting from N. asiatica infection diagnosed using thoracic CT in which the patient exhibited a rare radiological pattern of CMV pneumonia presenting as a cavitary lesion.
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